Roger A. Smith

3.6k total citations · 1 hit paper
60 papers, 2.8k citations indexed

About

Roger A. Smith is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, Roger A. Smith has authored 60 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Organic Chemistry, 23 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Roger A. Smith's work include Melanoma and MAPK Pathways (11 papers), Protease and Inhibitor Mechanisms (9 papers) and Peptidase Inhibition and Analysis (8 papers). Roger A. Smith is often cited by papers focused on Melanoma and MAPK Pathways (11 papers), Protease and Inhibitor Mechanisms (9 papers) and Peptidase Inhibition and Analysis (8 papers). Roger A. Smith collaborates with scholars based in United States, Canada and Germany. Roger A. Smith's co-authors include Jacques Dumas, Timothy B. Lowinger, Scott M. Wilhelm, Brian Schwartz, Christopher Carter, Susan L. Kelley, Mark Lynch, Ronit Simantov, David N. Harpp and Allen Krantz and has published in prestigious journals such as Journal of the American Chemical Society, Blood and Nature Reviews Drug Discovery.

In The Last Decade

Roger A. Smith

60 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

2006 1.4k citations Scott M. Wilhelm, Christopher Carter et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger A. Smith United States	21	1.4k	890	704	386	297	60	2.8k
Timothy B. Lowinger United States	20	1.3k 0.9×	742 0.8×	843 1.2×	475 1.2×	305 1.0×	53	2.7k
Steven L. Bender United States	16	1.1k 0.8×	742 0.8×	581 0.8×	257 0.7×	121 0.4×	26	2.1k
Jacques Dumas United States	22	1.7k 1.2×	1.0k 1.2×	1.1k 1.6×	435 1.1×	614 2.1×	46	3.9k
Mei‐Sze Chua United States	33	2.1k 1.5×	698 0.8×	585 0.8×	682 1.8×	262 0.9×	55	4.0k
Michele McTigue United States	18	1.7k 1.2×	388 0.4×	1.0k 1.4×	264 0.7×	225 0.8×	25	2.9k
Sylvie M. Guichard United Kingdom	33	2.3k 1.7×	555 0.6×	1.6k 2.2×	445 1.2×	271 0.9×	96	4.0k
Michel Vidal France	31	1.6k 1.1×	571 0.6×	897 1.3×	249 0.6×	105 0.4×	182	3.3k
László Őrfi Hungary	31	1.6k 1.2×	539 0.6×	1.0k 1.5×	228 0.6×	155 0.5×	113	3.3k
Peter Traxler Switzerland	30	2.7k 1.9×	1.1k 1.3×	1.6k 2.2×	420 1.1×	187 0.6×	61	4.6k
Ralf A. Hilger Germany	27	1.3k 1.0×	285 0.3×	1.2k 1.7×	374 1.0×	333 1.1×	83	3.2k

Countries citing papers authored by Roger A. Smith

Since Specialization

Citations

This map shows the geographic impact of Roger A. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger A. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger A. Smith more than expected).

Fields of papers citing papers by Roger A. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger A. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger A. Smith. The network helps show where Roger A. Smith may publish in the future.

Co-authorship network of co-authors of Roger A. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Roger A. Smith. A scholar is included among the top collaborators of Roger A. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger A. Smith. Roger A. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Roger A., David J. Zammit, Nitin K. Damle, et al.. (2021). ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models. Molecular Cancer Therapeutics. 20(8). 1327–1337. 19 indexed citations

Reddy, Sanjeeva, Niranjan Rao, David J. Zammit, et al.. (2017). Abstract 4204: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity in both hematological and solid tumor xenograft models. Cancer Research. 77(13_Supplement). 4204–4204. 5 indexed citations

Wilhelm, Scott M., Christopher Carter, Mark Lynch, et al.. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery. 5(10). 835–844. 1447 indexed citations breakdown →

Smith, Roger A., Jacques Dumas, Lila Adnane, & Scott M. Wilhelm. (2006). Recent Advances in the Research and Development of RAF Kinase Inhibitors. Current Topics in Medicinal Chemistry. 6(11). 1071–1089. 37 indexed citations

Smith, Roger A., Zahra Fathi, Su-Ellen Brown, et al.. (2006). Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives. Bioorganic & Medicinal Chemistry Letters. 17(3). 673–678. 18 indexed citations

Smith, Roger A. & Todd D. Giorgio. (2004). Cell-Based Screening: a High Throughput Flow Cytometry Platform for Identification of Cell-Specific Targeting Molecules. Combinatorial Chemistry & High Throughput Screening. 7(2). 141–151. 6 indexed citations

Ladouceur, Gaétan, James H. Cook, Donald L. Hertzog, et al.. (2002). Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 12(23). 3421–3424. 8 indexed citations

Smith, Roger A., Donald L. Hertzog, Martin H. Osterhout, et al.. (2002). Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis. Bioorganic & Medicinal Chemistry Letters. 12(9). 1303–1306. 13 indexed citations

Smith, Roger A., Jinshan Chen, Mary M. Mader, et al.. (2002). Solid-Phase synthesis and investigation of benzofurans as selective estrogen receptor modulators. Bioorganic & Medicinal Chemistry Letters. 12(20). 2875–2878. 22 indexed citations

10.

Smith, Roger A., et al.. (2001). Discovery and parallel synthesis of a new class of cathepsin k inhibitors. Bioorganic & Medicinal Chemistry Letters. 11(22). 2951–2954. 11 indexed citations

11.

Smith, Roger A., J A Barbosa, Mark A. Bobko, et al.. (2001). Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorganic & Medicinal Chemistry Letters. 11(20). 2775–2778. 70 indexed citations

12.

Dumas, Jacques, Robert Sibley, Bernd Riedl, et al.. (2000). Discovery of a new class of p38 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(18). 2047–2050. 34 indexed citations

13.

Smith, Roger A., Mark A. Bobko, & Wendy Lee. (1998). Solid-phase synthesis of a library of piperazinediones and diazepinediones via kaiser oxime resin. Bioorganic & Medicinal Chemistry Letters. 8(17). 2369–2374. 39 indexed citations

14.

Brömme, Dieter, Roger A. Smith, Peter J. Coles, et al.. (1994). Potent Inactivation of Cathepsins S and L by Peptidyl (Acyloxy)methyl Ketones. Biological Chemistry Hoppe-Seyler. 375(5). 343–348. 12 indexed citations

15.

Wagner, Bonnie M., Roger A. Smith, Peter J. Coles, et al.. (1994). In vivo Inhibition of Cathepsin B by Peptidyl (Acyloxy)methyl Ketones. Journal of Medicinal Chemistry. 37(12). 1833–1840. 27 indexed citations

16.

Ménard, Robert, Rong Feng, Andrew C. Storer, et al.. (1991). Nature of papain products resulting from inactivation by a peptidyl O‐acyl hydroxamate. FEBS Letters. 295(1-3). 27–30. 23 indexed citations

17.

Krantz, Allen, Leslie J. Copp, Peter J. Coles, Roger A. Smith, & Stephen B. Heard. (1991). Peptidyl (acyloxy)methyl ketones and the quiescent affinity label concept: the departing group as a variable structural element in the design of inactivators of cysteine proteinases. Biochemistry. 30(19). 4678–4687. 127 indexed citations

18.

Smith, Roger A., Peter J. Coles, Robin W. Spencer, et al.. (1988). Peptidyl O-acyl hydroxamates: Potent new inactivators of cathepsin B. Biochemical and Biophysical Research Communications. 155(3). 1201–1206. 33 indexed citations

19.

Smith, Roger A., Robert L. White, & Allen Krantz. (1988). Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site. Journal of Medicinal Chemistry. 31(8). 1558–1566. 26 indexed citations

20.

Smith, Roger A., Leslie J. Copp, Peter J. Coles, et al.. (1988). New inhibitors of cysteine proteinases. Peptidyl acyloxymethyl ketones and the quiescent nucleofuge strategy. Journal of the American Chemical Society. 110(13). 4429–4431. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact